Dyne Therapeutics, Inc. (DYN) Earnings History
Annual and quarterly earnings data from 2007 to 2025
Loading earnings history...
DYN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
DYN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export DYN earnings history in CSV or JSON format
Free sign-in required to download data
Dyne Therapeutics, Inc. (DYN) Earnings Overview
As of May 6, 2026, Dyne Therapeutics, Inc. (DYN) reported trailing twelve-month net income of -$446M, reflecting -3.0% year-over-year growth. The company earned $-3.47 per diluted share over the past four quarters.
Looking at the long-term picture, DYN's historical earnings data spans multiple years. The company achieved its highest annual net income of $264M in fiscal 2007.
Dyne Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($65M net income, -32.5% margin), CRSP (-$569M net income, -16569.8% margin), BMRN ($269M net income, 10.8% margin), DYN has comparable earnings metrics. Compare DYN vs SRPT →
DYN Earnings vs Peers
Earnings metrics vs comparable public companies
DYN Historical Earnings Data (2007–2025)
19 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$446M | -40.6% | -$468M | $-3.47 | - | - |
| 2024 | -$317M | -34.5% | -$344M | $-3.37 | - | - |
| 2023 | -$236M | -40.4% | -$242M | $-3.95 | - | - |
| 2022 | -$168M | -12.6% | -$171M | $-3.23 | - | - |
| 2021 | -$149M | -154.2% | -$150M | $-2.93 | - | - |
| 2020 | -$59M | -333.9% | -$59M | $-1.24 | - | - |
| 2019 | -$14M | -181.4% | -$14M | $-0.30 | - | - |
| 2018 | -$5M | -106.3% | -$5M | $-0.47 | - | - |
| 2017 | $76M | +106.1% | -$412M | $0.47 | 15.0% | -81.4% |
| 2016 | -$1.24B | -2580.0% | -$640M | $-9.61 | -90.8% | -46.9% |
See DYN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DYN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DYN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDYN — Frequently Asked Questions
Quick answers to the most common questions about buying DYN stock.
Is DYN growing earnings?
DYN EPS of $-3.47 reflects slowing growth at -3.0%, below the 5-year CAGR of N/A. TTM net income is $-446M. Expansion rate has moderated.
What are DYN's profit margins?
Dyne Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are DYN's earnings?
DYN earnings data spans 2007-2025. The current earnings trend is -3.0% YoY. Historical data enables comparison across business cycles.